- $180.81m
- $20.73m
- $53.43m
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Invivyd - Expects Liberty Trial Topline Data In Q3 2026
Brief: Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Invivyd Announces Completion Of Enrollment In Upsized Declaration Clinical Trial
Invivyd Q1 net loss per share misses on higher R&D costs
Brief: Invivyd Q1 EPS USD -0.13
Invivyd FY revenue rises; operating expenses cut sharply
Brief: Invivyd FY EPS USD -0.3 Vs. IBES Estimate USD -0.39
U.S. STOCKS ON THE MOVE-Allurion, Rithm Capital, Medtronic
U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines
Brief: Invivyd Partners With Lindsey Vonn To Educate Americans On Antibodies And Disease Prevention
Invivyd rises after team-up with Olympic skier Lindsey Vonn
U.S. STOCKS ON THE MOVE-Moderna, Seagate, Western Digital